Anti-HPV18 E7/Protein E7 Antibody (SAA2229) from ProteoGenix; catalogue ARO-A22609; research use only.
Know who made it. See the evidence. Buy through one marketplace.
The Anti-HPV18 E7/Protein E7 Antibody (SAA2229) is a highly specific and sensitive monoclonal antibody that targets the E7 protein of the human papillomavirus type 18 (HPV18). This protein is known to play a crucial role in the development and progression of cervical cancer, making it a key target for therapeutic and diagnostic purposes.
This antibody is primarily used in research studies and clinical applications related to HPV18 and cervical cancer. It can be used for the detection and quantification of E7 protein in various samples, including tissue lysates, cell lysates, and body fluids. It can also be used in immunohistochemistry and immunofluorescence assays to visualize the distribution and expression of E7 protein in tissues.
The Anti-HPV18 E7/Protein E7 Antibody (SAA2229) has been extensively used in various experimental settings to study the role of E7 protein in HPV18-associated diseases. It has been used to investigate the mechanisms of E7-induced cell transformation, as well as to evaluate the efficacy of potential anti-HPV18 therapies. Additionally, this antibody has been used in clinical trials to assess the expression levels of E7 protein in cervical cancer patients and its correlation with disease progression.
With its high specificity and sensitivity, the Anti-HPV18 E7/Protein E7 Antibody (SAA2229) is a valuable tool for researchers and clinicians studying HPV18 and cervical cancer. Its reliable performance and ease of use make it an essential component in the fight against this deadly disease.
Keywords: Anti-HPV18 E7/Protein E7 Antibody, monoclonal antibody, human papillomavirus type 18, cervical cancer, E7 protein, therapeutic, diagnostic, research, clinical applications, immunohistochemistry, immunofluorescence, cell transformation, anti-HPV18 therapies, clinical trials, disease progression, specificity, sensitivity, reliable, essential.
ProteoGenix catalogue number ARO-A22609. For research use only.
Target: E7; Clonality: Monoclonal Antibody; Applications: IP, ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| E7 |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
